Gene · 1806
Papers4,420
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
561 to 580 of 4,420
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Recurrent Reversible Stroke-Like Encephalopathy After 5-Fluorouracil (5-FU) Chemotherapy: A Case Report and Literature Review. | Am J Case Rep | 2023 | 37012696 | PubTator, text mining | PubMed |
| Long noncoding RNA SNHG6 silencing sensitized esophageal cancer cells to 5-FU via EZH2/STAT pathway. | Sci Rep | 2023 | 37005451 | PubTator, text mining | PubMed |
| Testing sulforaphane as a strategy against toxic chemicals of public health concern by toxicogenomic data analysis: Friend or foe at the gene level - Colorectal carcinoma case study. | Environ Res | 2023 | 37004859 | PubTator, text mining | PubMed |
| The Role of Gender Pharmacogenetics in the Personalization of Drug Treatment. | J Pharmacol Exp Ther | 2023 | 37001987 | PubTator, text mining | PubMed |
| The novel anti-cancer fluoropyrimidine NUC-3373 is a potent inhibitor of thymidylate synthase and an effective DNA-damaging agent. | Cancer Chemother Pharmacol | 2023 | 37000221 | PubTator, text mining | PubMed |
| Genomic sequencing has a high diagnostic yield in children with congenital anomalies of the heart and urinary system. | Front Pediatr | 2023 | 36999085 | PubTator, text mining | PubMed |
| Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond. | World J Gastroenterol | 2023 | 36998426 | PubTator, text mining | PubMed |
| Research progress of traditional Chinese medicine as sensitizer in reversing chemoresistance of colorectal cancer. | Front Oncol | 2023 | 36994201 | PubTator, text mining | PubMed |
| Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe. | ESMO Open | 2023 | 36989883 | PubTator, text mining | PubMed |
| Dendrimer-Mediated Delivery of Anticancer Drugs for Colon Cancer Treatment. | Pharmaceutics | 2023 | 36986662 | PubTator, text mining | PubMed |
| Analysis of MIR27A (rs11671784) Variant Association with Systemic Lupus Erythematous. | Life (Basel) | 2023 | 36983856 | PubTator, text mining | PubMed |
| Metoprolol and CYP2D6: A Retrospective Cohort Study Evaluating Genotype-Based Outcomes. | J Pers Med | 2023 | 36983598 | PubTator, text mining | PubMed |
| Optimizing Adjuvant Therapy after Surgery for Colorectal Cancer Liver Metastases: A Systematic Review. | J Clin Med | 2023 | 36983401 | PubTator, text mining | PubMed |
| MicroRNAs as Biomarkers of Surgical Outcome in Mesial Temporal Lobe Epilepsy: A Systematic Review. | Int J Mol Sci | 2023 | 36982768 | PubTator, text mining | PubMed |
| Influence of Single-Nucleotide Polymorphisms on Clinical Outcomes of Capecitabine-Based Chemotherapy in Colorectal Cancer Patients: A Systematic Review. | Cancers (Basel) | 2023 | 36980706 | PubTator, text mining | PubMed |
| Real-World Results of Raltitrexed Combined with S-1 and Bevacizumab in Heavily Pretreated Metastatic Colorectal Cancer. | Cancer Manag Res | 2023 | 36969545 | PubTator, text mining | PubMed |
| Moderately hypo-fractionated radiotherapy combined with S-1 in inoperable locally advanced esophageal squamous cell carcinoma: A prospective, single-arm phase II study (GASTO-1045). | Front Oncol | 2023 | 36969023 | PubTator, text mining | PubMed |
| Practical Notes on the Current ESMO Consensus Guidelines for the Management of Patients with Metastatic Colorectal Cancer in Resource-Constrained Environments of Low- to Middle-Income Countries. | Oncology | 2023 | 36958305 | PubTator, text mining | PubMed |
| A pilot study using immunohistochemical staining to characterize dihydropyrimidine dehydrogenase expression in keratinocyte neoplasms. | JAAD Int | 2023 | 36941911 | PubTator, text mining | PubMed |
ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C). | BMC Cancer | 2023 | 36941575 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1806/papers?page=29